Higher Cryopreserved CD34
Cord blood transplantation
Heparin
Sinusoidal obstruction syndrome
Thrombomodulin
Ursodeoxycholic acid
Veno-occlusive disease
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
27
06
2022
revised:
08
08
2022
accepted:
10
08
2022
pubmed:
23
8
2022
medline:
8
11
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is one of the most serious complications to occur early after allogeneic hematopoietic cell transplantation (HCT). However, detailed data on VOD/SOS after cord blood transplantation (CBT) are not available. The objective of this retrospective study was to evaluate the incidence, risk factors, and clinical impact of VOD/SOS after single-unit unrelated CBT for adult patients at our institution. We retrospectively evaluated the incidence, risk factors, and outcomes of VOD/SOS after 390 single-unit unrelated CBTs performed in 332 adults under a prophylactic strategy of ursodeoxycholic acid (UDCA) and i.v. heparin at our institution between 1998 and 2021. VOD/SOS was observed in 24 of the 390 CBTs. The cumulative incidence of VOD/SOS was 5.9% at 30 days and 6.2% at 100 days after CBT. Multivariate analysis showed that cryopreserved CD34
Identifiants
pubmed: 35995391
pii: S2666-6367(22)01552-4
doi: 10.1016/j.jtct.2022.08.013
pii:
doi:
Substances chimiques
Ursodeoxycholic Acid
724L30Y2QR
Antigens, CD34
0
Heparin
9005-49-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
779.e1-779.e9Informations de copyright
Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.